Introducción e Indice del Capítulo

1. Anhalt JG. Making sense of antigens and antibodies in pemphigus. J Am Acad Dermatol 1999; 40: 763 – 766.

2. Becker BA, Gaspari AA. Pemphigus vulgaris and vegetans. En: Crosby DL, Díaz LA. Bullous diseases. Dermatologic Clinics. W.B.Saunders, Filadelfia1993, 11: 429 – 452.

3. Shah N, Green AR, Elgart GW, et al. The use of chlorambucil with prednisone in the treatment of pemphigus. J Am Acad Dermatol 2000; 42: 85 – 88.

4. Amagai M. Pemphigus autoimmunity to epidermal cell adhesion molecules. En: James WD et al. Advances in Dermatology. Mosby, St Louis Missouri 1996, 11: 319 – 357.

5. Salazar AM, Faizal M. Tratamiento del pénfigo basado en una clasificación clínica, histológica y serológica. Rev Asoc Col Dermatol Cirug Dermat 1999; 7, 3: 215 – 233.

6. Vittorio CC, Werth U P. preventive techniques to limit glucocorticoid
induced side effects. Adv. Dermatol 2000; 16:273-298

7. Ahmed. A.R. Intravenous immunoglobulin therapy in the treatment of patients with Pemphigus vulgaris unresponsive to conventional inmunosupressive treatment.J. AM. Acad Dermatol 2001; 45: 679 - 690.

8. Dahl M. V, Bridges A. G. Intravenous immune globulin: fighting antibodies with antibodies.(Editorial). J. AM. Acad Dermatol 2001; 45: 775 – 783.

9. Ahmed A. R, Sami N. Intravenous immunoglobulin therapy for patients with Pemphigus foliaceus unresponsive to conventional therapy. J AM. Acad Dermatol 2002; 46: 42 – 49.

10. Bystrin JC ,Jiao D, Natow S. Treatment of penphigus with intravenous immunoglobulin.J. AM. Acad Dermatol 2002; 47: 358 – 363.